Key facts
- This page summarizes Richard M. Wright's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 17 Nov 2025, 16:17.
Richard M. Wright - 13 Nov 2025 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)
- Reporting relationship
- Former Officer
- Issuer ticker
- CLDX
- Reported as of
- 13 Nov 2025
- Net transaction value
- -$490,264
- SEC form
- 4
- Accepted by SEC
- 17 Nov 2025, 16:17:07 UTC
- Prior SEC filing
- 17 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sam Martin, attorney-in-fact for Richard M. Wright
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Richard M. Wright filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 17 Nov 2025.
Change
- Previous filing in this sequence was filed on 17 Jun 2024.
- Current net transaction value: -$490,264.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001646423
Primary reporting owner
Wright Richard M.
- Relationship
- Former Officer
- Address
- C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON
- Signature
- /s/ Sam Martin, attorney-in-fact for Richard M. Wright
- Signature date
- 17 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDX
transaction
Common Stock
Options Exercise
- Transaction value
- $61,997
- Shares
- +6,876
- Change %
- +33%
- Price
- $9.02
- Shares after
- 27,709
- Date
- 13 Nov 2025
- Ownership
- Direct
CLDX
transaction
Common Stock
Options Exercise
- Transaction value
- $276,855
- Shares
- +26,672
- Change %
- +96%
- Price
- $10.38
- Shares after
- 54,381
- Date
- 13 Nov 2025
- Ownership
- Direct
CLDX
transaction
Common Stock
Options Exercise
- Transaction value
- $354,060
- Shares
- +15,750
- Change %
- +29%
- Price
- $22.48
- Shares after
- 70,131
- Date
- 13 Nov 2025
- Ownership
- Direct
CLDX
transaction
Common Stock
Sale
- Transaction value
- $1,183,177
- Shares
- -49,298
- Change %
- -70%
- Price
- $24.00
- Shares after
- 20,833
- Date
- 13 Nov 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDX
transaction
Derivative
Incentive Stock Option
Options Exercise
- Transaction value
- $0
- Shares
- -6,876
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 13 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,876
- Exercise price
- $9.02
- Footnotes
- F2
CLDX
transaction
Derivative
Incentive Stock Option
Options Exercise
- Transaction value
- $0
- Shares
- -26,672
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 13 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,672
- Exercise price
- $10.38
- Footnotes
- F3
CLDX
transaction
Derivative
Incentive Stock Option
Options Exercise
- Transaction value
- $0
- Shares
- -15,750
- Change %
- -67%
- Price
- $0.000000
- Shares after
- 7,875
- Date
- 13 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,750
- Exercise price
- $22.48
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Richard M. Wright is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Footnote F2
As of June 13, 2022, the option is fully vested.
Footnote F3
As of June 18, 2024, the option is fully vested.
Footnote F4
25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.